Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,058 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder.
Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D, Fujihara K, Paul F, Cutter GR, Green AJ, Aktas O, Hartung HP, Lublin FD, Williams IM, Drappa J, She D, Cimbora D, Rees W, Smith M, Ratchford JN, Katz E, Cree BAC; N-MOmentum Study Investigators. Marignier R, et al. Among authors: paul f. Neurol Neuroimmunol Neuroinflamm. 2021 Mar 26;8(3):e978. doi: 10.1212/NXI.0000000000000978. Print 2021 May. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 33771837 Free PMC article. Clinical Trial.
Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica.
Paul F, Jarius S, Aktas O, Bluthner M, Bauer O, Appelhans H, Franciotta D, Bergamaschi R, Littleton E, Palace J, Seelig HP, Hohlfeld R, Vincent A, Zipp F. Paul F, et al. PLoS Med. 2007 Apr;4(4):e133. doi: 10.1371/journal.pmed.0040133. PLoS Med. 2007. PMID: 17439296 Free PMC article.
Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica.
Jarius S, Paul F, Franciotta D, Waters P, Zipp F, Hohlfeld R, Vincent A, Wildemann B. Jarius S, et al. Among authors: paul f. Nat Clin Pract Neurol. 2008 Apr;4(4):202-14. doi: 10.1038/ncpneuro0764. Epub 2008 Mar 11. Nat Clin Pract Neurol. 2008. PMID: 18334978 Review.
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients.
Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, Kleiter I, Kleinschnitz C, Berthele A, Brettschneider J, Hellwig K, Hemmer B, Linker RA, Lauda F, Mayer CA, Tumani H, Melms A, Trebst C, Stangel M, Marziniak M, Hoffmann F, Schippling S, Faiss JH, Neuhaus O, Ettrich B, Zentner C, Guthke K, Hofstadt-van Oy U, Reuss R, Pellkofer H, Ziemann U, Kern P, Wandinger KP, Bergh FT, Boettcher T, Langel S, Liebetrau M, Rommer PS, Niehaus S, Münch C, Winkelmann A, Zettl U UK, Metz I, Veauthier C, Sieb JP, Wilke C, Hartung HP, Aktas O, Paul F. Jarius S, et al. Among authors: paul f. J Neuroinflammation. 2012 Jan 19;9:14. doi: 10.1186/1742-2094-9-14. J Neuroinflammation. 2012. PMID: 22260418 Free PMC article.
Failure of natalizumab to prevent relapses in neuromyelitis optica.
Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung HP, Paul F, Aktas O; Neuromyelitis Optica Study Group. Kleiter I, et al. Among authors: paul f. Arch Neurol. 2012 Feb;69(2):239-45. doi: 10.1001/archneurol.2011.216. Arch Neurol. 2012. PMID: 22332191
1,058 results